...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Characterization of Antibodies to Capsular Polysaccharide Antigens of Haemophilus influenzae Type b and Streptococcus pneumoniae in Human Immune Globulin Intravenous Preparations
【24h】

Characterization of Antibodies to Capsular Polysaccharide Antigens of Haemophilus influenzae Type b and Streptococcus pneumoniae in Human Immune Globulin Intravenous Preparations

机译：人类免疫球蛋白静脉制剂中b型流感嗜血杆菌和肺炎链球菌荚膜多糖抗原抗体的表征

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The most common infections in primary immune deficiency disease (PIDD) patients involve encapsulated bacteria, mainly Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae (pneumococcus). Thus, it is important to know the titers of Hib- and pneumococcus-specific antibodies that are present in immune globulin (Ig) intravenous (IGIV) preparations used to treat PIDD. In this study, seven IGIV preparations were tested by enzyme-linked immunosorbent assay and opsonophagocytic activity for antibody titers to the capsular polysaccharides of Hib and five pneumococcal serotypes. Differences in Hib- and pneumococcus-specific antibody titer were observed among various IGIV preparations, with some products having higher- or lower-than-average titers. Opsonic activity also varied among preparations. As expected, IgG2 was the most active subclass of both binding and opsonic activity except against pneumococcal serotype 6B where IgG3 was the most active. This study determines antibody titers against capsular polysaccharides of Hib and pneumococcus in seven IGIV products that have been shown to be effective in reducing infections in PIDD patients. As donor antibody levels and manufacturing methods continue to change, it may prove useful from a regulatory point of view to reassess IGIV products periodically, to ensure that products maintain antibody levels that are important for the health of IGIV recipients.
机译：在原发性免疫缺陷疾病（PIDD）患者中，最常见的感染涉及包囊细菌，主要是流感嗜血杆菌（b）（Hib）和肺炎链球菌（肺炎球菌）。因此，重要的是要知道用于治疗PIDD的免疫球蛋白（Ig）静脉注射（IGIV）制剂中存在的Hib和肺炎球菌特异性抗体的效价。在这项研究中，通过酶联免疫吸附试验和调理吞噬活性测试了七种IGIV制剂对Hib荚膜多糖和五种肺炎球菌血清型的抗体效价。在各种IGIV制剂之间观察到Hib和肺炎球菌特异性抗体滴度的差异，有些产品的滴度高于或低于平均水平。调理活性在制剂之间也有所不同。正如预期的那样，除了针对肺炎球菌血清型6B（其中IgG3最活跃）以外，IgG2是结合和调理活性最活跃的亚类。这项研究确定了七种IGIV产品中针对Hib和肺炎球菌荚膜多糖的抗体效价，这些产品已被证明可有效减少PIDD患者的感染。随着供体抗体水平和生产方法的不断变化，从监管角度来看，定期重新评估IGIV产品可能很有用，以确保产品维持对IGIV受体健康至关重要的抗体水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号